Medicines in health and adult social care: Learning from risks and sharing good practice for better outcomes – Care Quality Commission

Care Quality Commission report that describes lessons for better medicines optimisation across health and social care providers and the positive impact of involving pharmacy professionals in health and social care settings.  

Clinical Commissioning Policy Statement: Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages) [170117P] – NHS England

This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).  

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Clinical Panel Report – NHS England

Clinical Panel report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Clinical Priorities Advisory Group Report – NHS England

Clinical Priorities Advisory Group report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours

Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages): Engagement Report – NHS England

Engagement report on Pazopanib for inoperable and metastatic malignant granular cell tumour (all ages). This policy statement is to confirm that pazopanib is not recommended as a treatment option for inoperable and metastatic malignant granular cell tumours (all ages).

Investigation into penalty charge notices in healthcare – National Audit Office

The NHS estimates that it lost around £212 million in 2017-18 from people incorrectly claiming exemption from prescription and dental charges. However rules around entitlement are overly complicated leading to genuine mistakes and confusion for many people. in response NHSBSA

Interim NHS People Plan: the future pharmacy workforce – NHS Improvement

Interim NHS People Plan, developed collaboratively with national leaders and partners, sets a vision for how people working in the NHS will be supported to deliver care and identifies the actions we will take to help them. It finds NHS

What is a Biosimilar Medicine? – NHS England

This document provides an update for key clinical and non-clinical stakeholders about the role of biosimilar medicines in the NHS in England and to support the safe, effective and consistent use of all biological medicines, including biosimilar medicines, to the

The community pharmacy: A guide for general practitioners and practice staff – Pharmaceutical Services Negotiating Committee

This updated guide aims to support general practitioners and community pharmacists in developing more effective working relationships and in turn, improve primary care services for patients. It covers key areas such as funding arrangements for pharmacies, the impact of prescribing

Summary of antimicrobial prescribing guidance – managing common infections: PHE context, references and rationales for Clinical Commissioning Groups, Commissioning Support Units and Primary Care Providers – Public Health England

Summary of antimicrobial prescribing guidance – managing common infections’ produced for primary and secondary care.

Cannabis-based products for medicinal use in humans: commission to the ACMD – Home Office

The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use. The ACMD issued their short-term advice on 19 July and 11 September with a

STOMP and STAMP: The Principles Behind the Pledge – NHS England

STOMP -STAMP (Stopping over medication of people with a learning disability, autism or both-Supporting Treatment and Appropriate Medication in Paediatrics) pledge resources for organisations and individuals that work with children and young people with a learning disability, autism or both

Making Outcome-Based Payment A Reality In The NHS – Office of Health Economics.

Report that explores the feasibility of introducing one type of flexible payment mechanism –outcome-based payment (OBP) –for cancer medicines into the NHS in England. This model links the price the NHS pays for a medicine to the outcomes it achieves

Understanding patient needs in switching from biologic to biosimilar medicines: Final report of survey and focus group findings – The Patients Association

Patients Association report that finds patients with common conditions such as rheumatoid arthritis, psoriasis and ulcerative colitis are being switched to new medicines without receiving the support they need to understand any changes, or to monitor and manage side effects

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation – Office for Health Economics

This report summarise research evaluating the main legal barriers to the better use of health data for pharmaceutical innovation. Issues are evaluated according to barriers arising in utilising data to support key activities across the lifecycle of a medicine: epidemiology

Clinical guidelines for major incidents and mass casualty events – NHS England

This guidance has been developed with the occasional trauma team in mind, for example, surgeons in a trauma unit who need to treat a deteriorating P2 patient, or a P1 patient who has been conveyed to the trauma unit, during

Cannabis-based medicines: an interim desktop guide – Royal College of General Practitioners

Report from the Royal College of General Practitioners giving an overview of the current legal situation regarding medicinal cannabis, the different forms it is available in, the conditions for which there is some, if limited, clinical evidence of benefit, and

The 2019 Voluntary Scheme For Branded Medicines Pricing And Access: Chapters And Glossary – Department of Health and Social Care

The voluntary scheme for branded medicines pricing and access is a non-contractual voluntary agreement between the Department of Health and Social Care (DHSC) and the Association of the British Pharmaceutical Industry (ABPI).  DHSC is acting on behalf of the UK government,

NHS Urgent Medicine Supply Advanced Service (NUMSAS) Training Module – NHS England

A training module developed for NHS 111 health advisors and pharmacy teams to help describe the NHS Urgent Medicine Supply Advanced Service (NUMSAS) and to illustrate the change in the patient journey since its introduction.

English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2018 – Public Health England

Fifth annual report of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR), which was established in 2013 to support Public Health England (PHE) in the delivery of the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018. It